These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9519805)

  • 1. Effects of an endothelin ET(A)-receptor antagonist, S-0139, on cerebral vasospasm and behavioral changes in dogs intracisternally administered endothelin-1.
    Sato S; Yonetani Y; Fujimoto M; Kita T; Kubo K; Nakashima T
    Life Sci; 1998; 62(13):PL191-7. PubMed ID: 9519805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiles of an intravenously available endothelin A-receptor antagonist, S-0139, for preventing cerebral vasospasm in a canine two-hemorrhage model.
    Kita T; Kubo K; Hiramatsu K; Sakaki T; Yonetani Y; Sato S; Fujimoto M; Nakashima T
    Life Sci; 1998; 63(4):305-15. PubMed ID: 9698039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin B receptor antagonists attenuate subarachnoid hemorrhage-induced cerebral vasospasm.
    Zuccarello M; Boccaletti R; Romano A; Rapoport RM
    Stroke; 1998 Sep; 29(9):1924-9. PubMed ID: 9731620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide endothelin antagonist. Cerebrovascular characterization and effects on delayed cerebral vasospasm.
    Willette RN; Zhang H; Mitchell MP; Sauermelch CF; Ohlstein EH; Sulpizio AC
    Stroke; 1994 Dec; 25(12):2450-5; discussion 2456. PubMed ID: 7974589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of endothelin-1 to disruption of blood-brain barrier permeability in dogs.
    Narushima I; Kita T; Kubo K; Yonetani Y; Momochi C; Yoshikawa I; Shimada K; Nakashima T
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):639-45. PubMed ID: 10619180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm.
    Wanebo JE; Arthur AS; Louis HG; West K; Kassell NF; Lee KS; Helm GA
    Neurosurgery; 1998 Dec; 43(6):1409-17; discussion 1417-8. PubMed ID: 9848855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs.
    Nirei H; Hamada K; Shoubo M; Sogabe K; Notsu Y; Ono T
    Life Sci; 1993; 52(23):1869-74. PubMed ID: 8318117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor subtype antagonist activity of S-0139 in various isolated rabbit and canine arteries.
    Iwasaki T; Hayasaki-Kajiwara Y; Shimamura T; Naya N; Nakajima M
    Eur J Pharmacol; 2000 Jul; 400(2-3):255-62. PubMed ID: 10988342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between the angiotensin and endothelin system in the cerebrovasculature after experimental induced subarachnoid hemorrhage.
    Wanderer S; Mrosek J; Vatter H; Seifert V; Konczalla J
    Neurosurg Rev; 2018 Apr; 41(2):539-548. PubMed ID: 28756589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cerebral vasospasm by a novel endothelin receptor antagonist, TA-0201.
    Kikkawa K; Saito A; Iwasaki H; Ban Y; Yasoshima A; Yamauchi-Kohno R; Hoshino T; Murata S
    J Cardiovasc Pharmacol; 1999 Nov; 34(5):666-73. PubMed ID: 10547082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm.
    Shigeno T; Clozel M; Sakai S; Saito A; Goto K
    Neurosurgery; 1995 Jul; 37(1):87-90; discussion 90-1. PubMed ID: 8587696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of endothelin in experimental cerebral vasospasm.
    Roux S; Löffler BM; Gray GA; Sprecher U; Clozel M; Clozel JP
    Neurosurgery; 1995 Jul; 37(1):78-85; discussion 85-6. PubMed ID: 8587695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists.
    Zuccarello M; Soattin GB; Lewis AI; Breu V; Hallak H; Rapoport RM
    J Neurosurg; 1996 Mar; 84(3):503-7. PubMed ID: 8609565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiographic studies on the effects of a novel calcium antagonist AE0047 on cerebral arteries in dogs, with special reference to the preventive effects of AE0047 on cerebral vasoconstriction induced by endothelin].
    Kido H; Uchida Y; Nakamura F; Sugimoto T
    Nihon Yakurigaku Zasshi; 1990 Apr; 95(4):177-84. PubMed ID: 2196210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog.
    Hirose H; Ide K; Sasaki T; Takahashi R; Kobayashi M; Ikemoto F; Yano M; Nishikibe M
    Eur J Pharmacol; 1995 Apr; 277(1):77-87. PubMed ID: 7635177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist.
    Zimmermann M; Seifert V; Löffler BM; Stolke D; Stenzel W
    Neurosurgery; 1996 Jan; 38(1):115-20. PubMed ID: 8747959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of TAK-044 on endothelin induced vasoconstriction in various canine arteries and porcine coronary arteries: a comparison with selective ETA and ETB receptor antagonists.
    Awane-Igata Y; Ikeda S; Watanabe T
    Br J Pharmacol; 1997 Feb; 120(3):516-22. PubMed ID: 9031758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoramidon inhibits the conversion of intracisternally administered big endothelin-1 to endothelin-1.
    Shinyama H; Uchida T; Kido H; Hayashi K; Watanabe M; Matsumura Y; Ikegawa R; Takaoka M; Morimoto S
    Biochem Biophys Res Commun; 1991 Jul; 178(1):24-30. PubMed ID: 2069564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rat model of endothelin-3-induced middle cerebral artery occlusion with controlled reperfusion.
    Henshall DC; Butcher SP; Sharkey J
    Brain Res; 1999 Oct; 843(1-2):105-11. PubMed ID: 10528116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction.
    Vatter H; Zimmermann M; Tesanovic V; Raabe A; Schilling L; Seifert V
    J Neurosurg; 2005 Jun; 102(6):1101-7. PubMed ID: 16028770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.